SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Kolominsky-Rabas PL, Sarti C, Heuschmann PU, Graf C, Siemonsen S, Neundoerfer B, Katalinic A, Lang E, Gassmann KG, Von Stockert TR. A prospective community-based study of Stroke in Germany – The Erlangen Stroke Project (espro) incidence and case fatality at 1, 3, and 12 months. Stroke 1998; 29: 25016.
  • 2
    Dawson J, Walters M. Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease? Br J Clin Pharmacol 2006; 62: 63344.
  • 3
    Weir CJ, Muir SW, Walters MR, Lees KR. Serum urate as an independent predictor of poor outcome and future vascular events after acute stroke. Stroke 2003; 34: 19516.
  • 4
    Berry C, Hamilton CA, Brosnan MJ, Magill FG, Berg GA, McMurray JJ, Dominiczak AF. Investigation into the sources of superoxide in human blood vessels: angiotensin II increases superoxide production in human internal mammary arteries. Circulation 2000; 9: 220612.
  • 5
    Dawson J, Quinn T, Walters M. Uric acid reduction: a new paradigm in the management of cardiovascular risk? Curr Med Chem 2007; 14: 187986.
  • 6
    Okamoto H, Mizuno K, Horio T. Monocyte-derived multinucleated giant cells and sarcoidosis. J Dermatological Sci 2003; 31: 11928.
  • 7
    Muir S, Harrow C, Dawson J, Lees KR, Weir CJ, Sattar N, Walters M. Allopurinol use yields potentially beneficial effects on inflammatory indices in those with recent ischemic stroke; a randomised, double blind placebo controlled trial. Stroke 2008; 39: 33037.
  • 8
    Khan F, George J, Wong K, McSwiggan S, Struthers AD, Belch JJF. Allopurinol treatment reduces arterial wave reflection in stroke survivors. Cardiovasc Ther 2008; 26: 24752.
  • 9
    Dawson J, Quinn TJ, Harrow C, Lees KR, Weir CJ, Cleland SJ, Walters MR. Allopurinol and nitric oxide activity in the cerebral circulation of those with diabetes. Diabetes Care 2009; 32: 1357.
  • 10
    Cupini LM, Diomedi M, Placidi F, Silvestrini M, Giacomini P. Cerebrovascular reactivity and subcortical infarctions. Arch Neurol 2001; 58: 57781.
  • 11
    Settakis G, Molnar C, Kerenyi L, Kollar J, Legemate D, Csiba L, Fulesdi B. Acetazolamide as a vasodilatory stimulus in cerebrovascular diseases and in conditions affecting the cerebral vasculature. Eur J Neurol 2003; 10: 60920.
  • 12
    Ringelstein EB, Sievers C, Ecker S, Schneider PA, Otis SM. Noninvasive assessment of Co-2-induced cerebral vasomotor response in normal individuals and patients with internal carotid-artery occlusions. Stroke 1988; 19: 9639.
  • 13
    Minematsu K, Yamaguchi T, Tsuchiya M, Ito K, Ikeda M, Omae T. Effect of Angiotensin Converting-Enzyme-Inhibitor (Captopril) on cerebral blood-flow in hypertensive patients without a history of stroke. Clin Exp Hypertens A 1987; 9: 5517.
  • 14
    Terborg C, Gora F, Weiller C, Rother J. Reduced vasomotor reactivity in cerebral microangiopathy – a study with near-infrared spectroscopy and transcranial Doppler sonography. Stroke 2000; 31: 9249.
  • 15
    Sterzer P, Meintzschel F, Rosler A, Lanfermann H, Steinmetz H, Sitzer M. Pravastatin improves cerebral vasomotor reactivity in patients with subcortical small-vessel disease. Stroke 2001; 32: 281720.
  • 16
    Walters M, Muir S, Shah I, Lees K. Effect of perindopril on cerebral vasomotor reactivity in patients with lacunar infarction. Stroke 2004; 35: 1899902.
  • 17
    Nazzaro P, Manzari M, Merlo M, Triggiani R, Scarano A, Ciancio L, Pirrelli A. Distinct and combined vascular effects of ACE blockade and HMG-CoA reductase inhibition in hypertensive subjects. Hypertension 1999; 33: 71925.
  • 18
    Schwertfeger N, Neu P, Schlattmann P, Lemke H, Heuser I, Bajbouj M. Cerebrovascular reactivity over time course in healthy subjects. J Neurol Sci 2006; 249: 1359.
  • 19
    Zocalli C, Maio R, Mallamaci F, Sesti G, Perticone F. Uric acid and endothelial dysfunction in essential hypertension. J Am Soc Nephrol 2006; 17: 146671.
  • 20
    Maxwell AJ, Bruinsma KA. Uric acid is closely linked to vascular nitric oxide activity. J Am Coll Cardiol 2001; 38: 18508.
  • 21
    Hare JM, Mangal B, Brown J, Fisher C, Freudenberger R, Colucci WS, Mann DL, Liu P, Givertz MM, Schwarz RP. Impact of oxypurinol in patients with symptomatic heart failure. J Am Coll Cardiol 2008; 51: 23019.
  • 22
    Gavin AD, Struthers AD. Allopurinol reduces B-type natriuretic peptide concentrations and haemoglobin but does not alter exercise capacity in chronic heart failure. Heart 2005; 91: 74953.
  • 23
    Mercuro G, Vitale C, Cerquetani E, Zoncu S, Deidda M, Fini M, Rosano GM. Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk. Am J Cardiol 2004; 94: 9325.
  • 24
    Doehner W, Anker SD. Xanthine oxidase inhibition for chronic heart failure: is allopurinol the next therapeutic advance in heart failure? Heart 2005; 91: 7079.
  • 25
    George J, Carr E, Davies J, Belch JJ, Struthers A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 2006; 114: 250816.
  • 26
    Dahl A, Russell D, Rootwelt K, Nyberghansen R, Kerty E. Cerebral vasoreactivity assessed with transcranial Doppler and regional cerebral blood-flow measurements – dose, serum concentration, and time-course of the response to acetazolamide. Stroke 1995; 26: 23026.
  • 27
    Hamann GF, Stoll M, Jost V, Bompotti UAR, Fitridge R, Schimrigk K. Time course of acetazolamide effect in normal persons. J Neuroimaging 1996; 6: 2931.
  • 28
    West GA, Leppla DC, Simard JM. Effects of external pH on ionic currents in smooth-muscle cells from the basilar artery of the guinea-pig. Circ Res 1992; 71: 2019.
  • 29
    Hauge A, Nicolaysen G, Thoresen M. Acute effects of acetazolamide on cerebral blood-flow in man. Acta Physiol Scand 1983; 117: 2339.
  • 30
    Pretnar-Oblak J, Sabovic M, Vidmar G, Zaletel M. Evaluation of L-arginine reactivity in comparison with flow-mediated dilatation and intima-media thickness. Ultrasound Med Biol 2007; 33: 154651.
  • 31
    Prettlar-Oblak J, Sabovic M, Sebestjen M, Pogacnik T, Zaletel M. Influence of atorvastatin treatment on l-arginine cerebrovascular reactivity and flow-mediated dilatation in patients with lacunar infarctions. Stroke 2006; 37: 25405.